Short Interest in Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Decreases By 13.7%

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) was the recipient of a significant decline in short interest in the month of March. As of March 15th, there was short interest totalling 774,400 shares, a decline of 13.7% from the February 28th total of 897,700 shares. Currently, 3.7% of the shares of the stock are sold short. Based on an average trading volume of 1,100,000 shares, the short-interest ratio is presently 0.7 days.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the stock. Lake Street Capital cut their price target on shares of Ekso Bionics from $2.00 to $1.00 and set a “buy” rating for the company in a report on Tuesday, March 4th. StockNews.com started coverage on shares of Ekso Bionics in a report on Thursday, March 27th. They set a “hold” rating for the company. Finally, HC Wainwright reiterated a “buy” rating and set a $9.00 price objective on shares of Ekso Bionics in a research report on Tuesday, March 4th.

Ekso Bionics Trading Up 1.1 %

Shares of EKSO stock traded up $0.00 during trading hours on Wednesday, reaching $0.41. 38,496 shares of the stock traded hands, compared to its average volume of 345,672. The company has a quick ratio of 2.14, a current ratio of 2.81 and a debt-to-equity ratio of 0.28. The firm has a market capitalization of $10.18 million, a PE ratio of -0.63 and a beta of 1.43. Ekso Bionics has a 1-year low of $0.34 and a 1-year high of $1.53. The business has a fifty day moving average price of $0.51 and a 200 day moving average price of $0.73.

Ekso Bionics (NASDAQ:EKSO) last issued its quarterly earnings results on Monday, March 3rd. The company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.07). The business had revenue of $5.09 million for the quarter, compared to analysts’ expectations of $5.05 million. Ekso Bionics had a negative net margin of 62.95% and a negative return on equity of 83.09%. On average, equities research analysts forecast that Ekso Bionics will post -0.48 EPS for the current year.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.